Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Administration, Buccal”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1991

Bioavailability of flurbiprofen following buccal administration.

The buccal absorption of flurbiprofen was evaluated in nine normal volunteers. Twenty milliliters of 2.5 mg/ml flurbiprofen solution (pH 8.03) was administered as a 1-min mouthwash or a 5-min mouthwash or swallowed. Serum was harvested from blood samples taken at specified times over a 12-hr period. Serum flurbiprofen concentration data indicate that the extent, but not the rate, of drug absorption was dependent upon the time of exposure of the flurbiprofen solution to the buccal membrane. Following the 1- and 5-min mouthwash treatments, 5.2 and 9.4% of the administered doses were absorbed, respectively.

Administration, Buccal↗
PubMed1987

Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs.

The pharmacokinetics of meperidine was studied in Beagle dogs following intravenous, peroral and buccal administration of a meperidine hydrochloride solution. The elimination half-life after I.V., P.O. and buccal routes was 0.75 +/- 0.14 hours, 0.93 +/- 0.18 hours and 0.36 +/- 0.10 hours, respectively. The volume of distribution and total clearance following I.V., P.O. and buccal administration were 2.41 +/- 0.34 L/kg and 42.5 +/- 8.9 ml/min/kg, 2.84 +/- 1.24 L/kg and 34.6 +/- 7.8 ml/min/kg, 1.01 +/- 0.52 L/kg and 34.7 +/- 8.0 ml/min/kg, respectively. The absolute bioavailability after P.O. and buccal administration was 11.0 +/- 6.8% and 11.9 +/- 6.6%, respectively. This paper discusses the observed low bioavailabilities on hypothesis of hepatic and lung first-pass effect. A hypothesis is presented to explain the delayed onset of absorption following buccal administration.

Administration, Buccal↗
PubMedDate not supplied

[Hemodynamic and methabolic aspects of sodium nitroprusside pharmacodynamics during buccal administration in patients with arterial hypertension of cerebral ischemic genesis].

The authors presented in the article efficiency of new formulation of Natrium Nitroprusodum used buccaly in patients with cerebral-ischemic form of arterial hypertention and stage II hypertention. It has been shown both in an acute experiment and after monothrerapy having been used. The medication proved to have positive effect on brachiocephalic vessel blood flow indices in patients of both groups using pulse doplergraphy. The use of Natrium Nitroprussidum used buccaly in patients with cerebral-ischemic form of arterial hypertention and hyportensive disease differentiates in terms of indices characterising the formation, transport and utilisation of energetic products, products of POL and antioxidant ferments.

Administration, Buccal↗
PubMed2002

Development of polymer film dosage forms of lidocaine for buccal administration: II. Comparison of preparation methods.

In previous studies, we prepared film dosage forms of lidocaine (LC) with hydroxypropylcellulose (HPC) as a film base using the solvent evaporation (SE) method. However, from the viewpoint of environmental issues, a reduction in organic solvent use in pharmaceutical and other industries is required. In this study, we prepared the LC films by direct compression of the physical mixture (DCPM method) and direct compression of the spray dried powder (DCSD method). Magnesium stearate, which was required as a lubricant for direct compression, showed no effect on the LC release rate. The LC release rate (%/h) was independent of the compression pressure, but a higher pressure was preferable to easily remove the film from the punches. An increase in the film weight decreased the LC release rate expressed in %/h, whereas no significant effect of film weight was observed on the LC release rate from unit surface area expressed in mg/h/cm(2). The LC release rate (%/h) was independent of the LC content, suggesting that the LC release rate (mg/h) can be quantitatively controlled by changing the LC content in the formulation. The LC release rate and penetration rate were affected by the preparation method; that is, DCPM method < DCSD method < SE method. The LC penetration rates through excised hamster oral mucosa were linearly correlated to the release rate of un-ionized LC, which was estimated by the LC release rate multiplied by the un-ionized fraction of LC for the HPC film dosage form.

Administration, Buccal↗
PubMed2001

Development of polymer film dosage forms of lidocaine for buccal administration. I. Penetration rate and release rate.

We examined the penetration rate of lidocaine (LC) through excised oral mucosa from hamster cheek pouch and the in vitro release rate of LC from film dosage forms with hydroxypropylcellulose (HPC) as a film base. Addition of glycyrrhizic acid (GL) to the HPC films increased the LC release rate almost GL-content-dependently, while an optimum GL content was observed for the LC penetration rate. No LC penetration was observed from an acidic aqueous solution (pH 3.4) of LC, suggesting only unionized LC can substantially penetrate through the mucosa. A significant relationship between the penetration rate of LC and the release rate of unionized LC was found, suggesting that the in vitro dissolution study is a useful tool to predict the penetration rate taking the unionized drug fraction into consideration.

Administration, Buccal↗
PubMed1994

Effect of buccal administration of a lactose-containing nitroglycerin tablet (Suscard) on plaque pH.

The aim of this study was to monitor pH in 2-day-old dental plaque after administration of a long-acting, lactose-containing nitroglycerin tablet (Suscard). The tablet was placed under the lip of the maxilla. This was done both in two older subjects suffering from heart problems and in 10 younger, healthy subjects. In the latter group, a sucrose-containing lozenge was used as a control. The influence of a 5-wk period of daily use of Suscard (in the two elderly subjects) and the effect of normal oral hygiene procedures (in the 10 younger subjects) on the pH response was also studied. Plaque pH was measured in situ up to 1 h, at five different approximal sites in the front region of the maxilla by the micro-touch method. The Suscard tablet resulted in a fall in plaque pH in both groups when teeth had not been brushed for 2 days. The lowest pH was recorded at the sites close to where the tablet had been placed. The most attenuated pH drop was found in the two older subjects, who showed a mean minimum pH of 5.7, as compared with 6.2 for the younger subjects. No further increase in the pH fall from Suscard was seen after the 5-wk period in the two patients with heart problems. In the 10 younger healthy subjects, the most pronounced pH decrease was registered after administration of the sucrose-containing lozenge. The pH drop for Suscard was not significant when normal oral hygiene procedures preceded the test.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Buccal↗
PubMed1991

Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs.

This in vivo study was designed to obtain bioavailability data and a definite pharmacokinetic profile of papaverine HCl in Beagle dogs following intravenous (IV), peroral (PO), rectal, vaginal, topical, and buccal administration of different papaverine HCl formulations. Blood samples were analyzed by high-performance liquid chromatography. The pharmacokinetic parameters were determined using either a curve fitting program (RESID) or a compartment model independent program (AUC-RPP). The plasma concentration-time profiles show that papaverine HCl pharmacokinetics is best described by an open two-compartment model. The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.

Administration, Buccal↗
PubMed1998

Midazolam pharmacokinetics following intravenous and buccal administration.

AIMS: Midazolam has good anxiolytic qualities and is a well established premedication agent before anaesthesia or short surgical procedures. The objective of the present study was to determine pharmacokinetic data from individual plasma concentration profiles obtained following intravenous and buccal administration of midazolam. METHODS: Eight young healthy volunteers received single doses of 5 mg midazolam i.v. and after a period of 1 week buccally in a cross over manner. Blood samples were obtained up to 480 min. The measurement of plasma midazolam concentrations was by gas-chromatography. RESULTS: The maximum plasma concentration was 55.9 ng ml(-1) (range 35.6-77.9 ng ml(-1)) at 30 min (range 15-90 min) following buccal administration. AUC was calculated to be 15016 ng ml(-1) min (s.d. 3778 ng ml(-1) min) following i.v. and 11191 ng ml(-1) min (s.d. 1777 ng ml(-1) min) following buccal midazolam. This gave a mean midazolam bioavailability of 74.5%. CONCLUSIONS: The pharmacokinetic data presented in this study demonstrate a high bioavailability and reliable plasma concentrations following buccal midazolam. The clinical benefit of buccal midazolam may be in particular patient controlled premedication or sedation in adults.

Administration, Buccal↗
PubMed1995

Absorption of clonazepam after intranasal and buccal administration.

Serum concentrations of clonazepam after intranasal, buccal and intravenous administration were compared in a cross-over study in seven healthy male volunteers. Each subject received a 1.0 mg dose of clonazepam intranasally and buccally and 0.5 mg intravenously. A Cmax of 6.3 +/- 1.0 ng ml-1 (mean; +/- s.d.) was measured 17.5 min (median) (range 15-20 min) after intranasal administration. A second peak (4.6 +/- 1.3 ng ml-1) caused by oral absorption was seen after 1.7 h (range 0.7-3.0 h). After buccal administration a Cmax of 6.0 +/- 3.0 ng ml-1 was measured after 50 min (range 30-90 min) with a second peak of 6.5 +/- 2.5 ng ml-1 after 3.0 h (range 2.0-4.0 h). Two minutes after i.v. injection of 0.5 mg clonazepam the serum concentration was 27 +/- 18 ng ml-1. It is concluded that intranasal clonazepam is an alternative to buccal administration. However, the Cmax of clonazepam after intranasal administration is not high enough to recommend the intranasal route as an alternative to intravenous injection.

Absorption↗
PubMedDate not supplied

Bioadhesive polymer-grafted starch microspheres bearing isosorbide dinitrate for buccal administration.

A polymer-grafted mucoadhesive system bearing isosorbide dinitrate was prepared for buccal administration. Polymer grafting of starch microspheres modified drug release and surface characteristics of microspheres. Bioadhesion and factors affecting bioadhesion were studied. Process variables that could affect microsphere size, and as a result the release of the drug, were also studied. It was observed that compression of grafted starch microspheres modified drug release and extended drug action via slow release following buccal application. Prepared system(s) were characterized for drug release and in vivo performance and compared with conventional oral treatment. The systems were noted to be promising.

Adhesiveness↗